Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO IYII) epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 236-244

  Skírnisdóttir, Ingirídur Anna ^a,d   Sorbe, Bengt ^b   Lindborg, Katarina ^a   Seidal, Tomas ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c Halmstad Regional Hospital   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

C MYC; Early stages; Ovarian cancer; P27; P53; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; MYC PROTEIN; PACLITAXEL; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS; MAJOR CLINICAL STUDY; ONCOGENE C MYC; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, MYC; GENES, P53; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 79956084010     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820986e5     Document Type: Article

References (30)

1. Kurman RJ, Visvanathan K, Roden R, et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008;4:351-356. (Pubitemid 351451941)
2. Darcy KM, Brady WE, McBroom JW, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelian ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;111:478-495.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. (Pubitemid 46148091)
4. Köbel M, Kalloger SE, Santos JL, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol. 2010;116:50-56.
5. Nam EJ, Kim YT. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18: 1169-1182.
6. Foster I. Cancer: a cell cycle defect. Radiography. 2008;14: 144-149. (Pubitemid 351400416)
7. Palmer JE, Sant Cassia LJ, Irwin CJ, et al. p53 and bcl-2 assessment in serous carcinoma. J Gynecol Cancer. 2008;18:241-248. (Pubitemid 351365201)
8. (KIP1), TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol. 2003;14:1078-1085. (Pubitemid 36950172)
9. Lee Y-K, Park N-H. Prognostic value and clinico-pathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol Oncol. 2009;112:475-480.
10. Petijean A, Achatz MI, Borresen-dale AL, et al. TP53 mutation in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26: 2157-2165. (Pubitemid 46536647)
11. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485-495. (Pubitemid 30137934)
12. (KIP1) levels during tumor development. Cancer cell. 2006;2:75-76. (Pubitemid 43202657)
13. Masciullo V, Susini MV, Zamparelli A, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 (Kip1) in estrogen-related endometrial adenocarcinomas. Women's Oncol Rev. 2004;4:19-20.
14. Skirnisdottir I, Sorbe B, Seidal T. p53, bcl-2, bax; their relationship and effect on prognosis in early stage ovarian carcinoma. Int J Gynecol Cancer. 2001;11:241-248.
15. Lassus H, Leminen A, Lundin J, et al. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003;91:504-512. (Pubitemid 38388142)
16. Skirnisdottir I, Sorbe B, Seidal T. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer. 2004;14:259-270. (Pubitemid 38533897)
17. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 95. 2003;18:113-125. (Pubitemid 36193260)
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847. (Pubitemid 28331029)
19. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol. 2001;25: 1204-1207. (Pubitemid 32777722)
20. Gadducci A, Cosio S, Tana R, et al. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Critical Rewievs Oncol/Hematol. 2009;69: 12-27.
21. Chen CH, Shen J, Lee WJ, et al. Overexpression of cyclin D and C-MYC gene products in human primary epithelial ovarian cancer. Int J Gynecol Cancer. 2005;15:878-883. (Pubitemid 41783096)
22. Baekelandt M, Holm R, Tropé CG, et al. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin cancer Res. 1999;5:2848-2853. (Pubitemid 29493962)
23. Shimizu M, Nikaido T, Toki T, et al. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer. 1999;85: 669-677. (Pubitemid 29075288)
24. Skirnisdottir I, Seidal T, Karlsson M, et al. Clinical and biological characteristics of clear cell carcinoma of the ovary in FIGO-stages I-II. Int J Oncol. 2005;26:177-183.
25. Reles A, Schmider A, Press MF, et al. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol. 1996; 122:489-494. (Pubitemid 26248241)
26. Anttila MA, Ji H, Juhola MT, et al. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol. 1999;18:42-51. (Pubitemid 29028843)
27. kip1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol. 1999;154:119Y125. (Pubitemid 29031619)
28. kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res. 2000;6:4816-4822. (Pubitemid 32110425)
29. Darcy KM, Brady WE, Blancato JK, et al. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resedted advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;114:472-479.
30. Hennessy BT, Markman M. Development of novel agents for ovarian cancer. Update Cancer Ther. 2009;3:119-132.